title: Outsourcing to exploit a key asset.
abstract: Much has been written and debated about the economic and organizational advantages of outsourcing a growing list of operations in drug discovery. In what has been described as a modular approach to drug discovery, whole sections of the process are now handled very effectively by a wide variety of specialist suppliers to the pharmaceutical industry. Here we report on a novel outsourced solution to the challenge of consolidating and managing some of the key assets residing within a major research organization - its chemical intermediates. At Johnson and Johnson Pharmaceutical Research and Development this resource has been built up over a period of more than 40 years, and is added to daily. The challenge was to provide the company's scientists with a single source for its own and externally procured intermediates; the solution was developed working in partnership with Sigma-Aldrich.
authors.affiliation: Department of Medicinal Chemistry, Pharma IM R&D, Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica, Turnhoutseweg 30 B-2340 Beerse, Belgium. lmeerpoe@prdbe.jnj.com
authors.forename: Lieven
authors.initials: L
authors.lastname: Meerpoel
authors.forename: Marc
authors.initials: M
authors.lastname: Schroven
authors.forename: Koen
authors.initials: K
authors.lastname: Goris
authors.forename: Koen
authors.initials: K
authors.lastname: Demoen
authors.forename: Siobhan
authors.initials: S
authors.lastname: Marsden
mesh_terms: D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration / Q000592:standards; D020416:Outsourced Services